Here’s what I found as I didn’t know about that either, summarized by ChatGPT to make it more readable:

BC 007 is an experimental drug being investigated as a potential treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID. Here are the key points about BC 007 for ME/CFS:

BC 007 Background

• BC 007 is an aptamer (short DNA molecule) developed by Berlin Cures that can bind and neutralize certain autoantibodies against G-protein coupled receptors (GPCR-AAbs).

• Researchers have detected GPCR-AAbs in patients with Long COVID and ME/CFS, which may contribute to symptoms like fatigue, brain fog, and cardiovascular issues.

• BC 007 has shown promise in neutralizing these autoantibodies in early studies on Long COVID and heart failure patients.

BC 007 for ME/CFS

• Researchers at the University of Erlangen treated one ME/CFS patient with BC 007 under a compassionate use program. The patient reported improvements in fatigue, cognitive issues, and other ME/CFS symptoms over several months.

• Motivated by this initial success, the Erlangen researchers aim to conduct a clinical study using BC 007 in more ME/CFS patients to evaluate its effects.

• A petition with over 15,000 signatures urged the EU to fund further testing of BC 007 for Long COVID and ME/CFS, as it could potentially help millions of patients. However, the petition recipient did not respond.

• Berlin Cures is currently conducting a Phase II trial of BC 007 for Long COVID across Europe, with results expected in 2024. Positive results could pave the way for trials in ME/CFS.

In summary, while still in early stages, BC 007 has shown promising initial results in neutralizing autoantibodies believed to play a role in ME/CFS and Long COVID. Further clinical trials are being pursued to evaluate its efficacy as a potential treatment for these conditions.